Portfolio yield
Data as at : 31/03/2026
| % |
|---|
| 1.1 |
Please note that the above fields are displayed for companies that have reported this data to the AIC. Where data is reported, it may be subject to valuation lags.
Top holdings
Data as at : 31/12/2025
| Investment | % of total assets |
|---|---|
| Eli Lilly and Co | 13.5 |
| Boston Scientific Corp | 8.8 |
| AstraZeneca PLC | 8.7 |
| Edwards Lifesciences Corp | 6.1 |
| Intuitive Surgical Inc | 5.8 |
| Stryker Corp | 4.5 |
| argenx SE ADR | 3.8 |
| Alnylam Pharmaceuticals Inc | 3.4 |
| Natera Inc | 2.7 |
| Caris Life Sciences Inc | 2.5 |
Geographic breakdown
Data as at : 31/03/2026
| Country | % of total assets |
|---|---|
| USA | 62.3 |
| China | 6.8 |
| UK | 6.0 |
| Netherlands | 4.3 |
| Switzerland | 4.1 |
| Japan | 2.3 |
| Belgium | 1.6 |
| Hong Kong | 1.5 |
| France | 1.3 |
| Canada | 1.3 |
| Denmark | 1.1 |
| India | 0.3 |
Depending on the nature of the underlying asset classes, geographic breakdowns may not always add up to 100%.
Industry breakdown
Data as at : 31/03/2026
| Industry | % of total assets |
|---|---|
| Healthcare | 91.4 |
| Cash Equivalents | 5.1 |
| Preferred | 1.9 |
Asset breakdown
Data as at : 31/03/2026
| Asset | % of total assets |
|---|---|
| Stock | 93.4 |
| Other | 1.5 |
| Cash/Cash equivalents | 5.1 |
Detailed asset breakdown
Data as at : 31/03/2026
| Asset | % of total assets |
|---|---|
| North America - stock | 68.4 |
| UK - Large core/growth stock | 6.1 |
| Europe - Large-cap stock | 5.8 |
| Asia (excl Japan) - stock | 5.6 |
| Cash | 5.1 |
| Japan - stock | 2.3 |
| Preferred stock | 1.9 |
| Other | 1.5 |
| Europe - Mid-cap stock | 1.3 |
| Other - stock | 1.2 |
Data provided by Morningstar.
Company documents provided by FE fundinfo.